Some of the first preclinical studies have shown that risdiplam can reach the central nervous system and peripheral organs in vivo and can lead to significant increases in SMN protein levels in blood, brain, and muscle, with increased survival in various mouse models of SMA [100,101]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.